

PTO/SB/08a/b (08-03)


Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/612,599
				Filing Date	July 2, 2003
				First Named Inventor	Richard Rox Anderson
				Art Unit	3763 Aarti Bhatia
				Examiner Name	Nicholas D. Luchesi
Sheet	1	of	1	Attorney Docket Number	101537-38

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
/A.B./ ↓		4,803,069	02/07/1989	Kekesi et al.	
		6,183,773	02/06/2001	Anderson	
		6,600,951	07/29/2003	Anderson	
		2002/0087205	07/04/2002	Chen	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
/A.B./		CA 2,190,378	11/23/1995	Bioglan Laboratories Ltd.		
		EP 0 726 083 A3	12/16/1998	Eckhouse		
		WO 96/09853	04/04/1996	The General Hospital Corporation		
		WO 00/40266	07/13/2000	The General Hospital Corporation		
		WO 01/55092	08/02/2001	Burmeister Gerd	Abstract	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/A.B./		Divaris, D. et al., "Phototoxic Damage to Sebaceous Glands and Hair Follicles of Mice After Systemic Administration of 5-Aminolevulinic Acid Correlates with Localized Protoporphyrin IX Fluorescence," Am. J. Pathol. 136(4):891-897 (1990).	
		Hongcharu et al., "Topical ALA-Photodynamic Therapy for the Treatment of Acne Vulgaris," Soc. for Invest. Derm., Inc. pp. 1-9 (J. Invest. Derm. pp. 115(2):183-192) (2000).	
		Kloek, J. et al., "Prodrugs of 5-Aminolevulinic Acid for Photodynamic Therapy," Photochem & Photobiol. 64(6):994-1000 (1996).	
		Peng et al., "Build Up of Esterfield Aminolevulinic Acid-Derived-Induced Porphyrin Fluorescence in Normal Mouse Skin," J. Photochem. & Photobiol. B. Biol. 34:95-96 (1996).	
		Pento, J.T., "Delta-Aminolevulinic Acid, Photodynamic Therapy, Antineoplastic, Agent for Actinic Keratoses, Antiacne," Drugs of the Future 22(1):11-17 (1997).	
		Rhodes, L.E. et al., "Iontophoretic Delivery of ALA Provides a Quantitative Model for ALA Pharmacokinetics and PpIX Phototoxicity in Human Skin," J. Invest. Dermatol. 108:87-91 (1997).	
		Sharman, W. et al., "Photodynamic Therapeutics: Basic Principles and Clinical Applications," Drug Discovery Today 4(11):507-517 (1999).	
		Shulman, D., "DUSA Pharmaceuticals Reports Encouraging Results in Phase I/II Acne Clinical Trial," DUSA Pharmaceuticals Inc., Mississauga (10/7/1996).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

1601725.1

Examiner Signature	/Aarti Bhatia/	Date Considered	03/25/2008
--------------------	----------------	-----------------	------------